Navigation Links
PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Date:9/3/2009

nly FDA-approved indication for such products. However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About Bacillus - ACT 2009

Bacillus - ACT 2009 is the third joint conference representing a fusion of two conferences: the 8th International Conference on Anthrax and the 6th International Workshop on the Molecular Biology of Bacillus cereus, Bacillus anthracis and Bacillus thuringiensis, and is organized by the American Society for Microbiology (ASM). The major mission of the conference is to promote stimulating and fruitful interactions between investigators involved in research related to the physiology, genetics, molecular biology, and pathogenicity of these bacteria and to the prevention and treatment of diseases they cause. The conference includes scientific sessions consisting of oral or poster presentations selected from the abstract submissions.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim((R))-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia((R)) -- a novel bioscavenger for the prevention and treatme
    '/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
(Date:7/1/2015)... InferMed , s decision ... augment Elsevier ... suite   Elsevier , a world-leading provider ... today the acquisition of  InferMed , a London ... InferMed,s Arezzo technology supports clinicians in choosing the most appropriate ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) ... CTI’ new Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. ... device that will increase healthcare worker safety and reduce financial costs. , CTI ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... LLC is extremely proud to,announce the release of its ... provides full end to end workflow,capability for radiology facilities ... Harsha Hatti, President and CEO of PETLinQ, states, ... respected and highly credible operating system that,many radiologists and ...
... 18 ,Benda Pharmaceutical, Inc. (OTC Bulletin Board: BPMA), a ... for the treatment of cancer, and traditional Chinese and,conventional ... month periods ended September 30, 2008. The Company ... , Nine Months ...
... extensive experience in multi-GPU high-performance computing systems ... provide scientists, engineers and researchers with a ... Supercomputer (PSC), which will be shown at ... SC08 Conference, the top international conference for ...
Cached Biology Technology:PETLinQ Launches RISLinQ 4.0Mac on Mac OS X Platform 2Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 2Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 3Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 4Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 5Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 6Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 7Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 8Benda Pharmaceutical Reports Third Quarter 2008 Financial Results 9BOXX Personal Supercomputer for Research Scientists Featured at SC08 2
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/23/2015)... , June 23, 2015   MedNet ... that supports the entire spectrum of clinical research, ... ™ , the company,s intuitive, flexible ... awarded a Silver 2015 Stevie® Award by the ... Products & Services Website category.  The American Business ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... REM sleep deprivation procedure reduces cell proliferation in the ... of rats, according to a study published in the ... study, authored by Dennis McGinty, PhD, of the V.A. ... rats. REM sleep deprivation was achieved by a ...
... developed by researchers at the University of Michigan more ... currently in use, according to a study published in ... of the American Association for Cancer Research. The ... for the presence of four different RNA molecules accurately ...
... worlds poorest regions could face severe crop losses in the ... new study by researchers at Stanford Universitys Program on Food ... published in the Feb. 1 issue of the journal Science. ... on agriculture for their livelihoods, said lead author David Lobell, ...
Cached Biology News:4 days of REM sleep deprivation contributes to a reduction of cell proliferation in rats 2New, noninvasive prostate cancer test beats PSA in detecting prostate cancer 2New, noninvasive prostate cancer test beats PSA in detecting prostate cancer 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 2Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 3Impoverished areas of Africa and Asia face severe crop losses from climate change in 20 years 4
... a chromogenic medium for the detection, ... (except S. thyphi) and total coliforms ... takes a maximum of 24 hours, ... sterilization during preparation and performs a ...
This modular benchtop laminar flow hood forces air through a 99.99% efficient HEPA filter to create a clean processing area. Options include a work bench, ionizaing bar, and air velocity gauge....
...
... Scientific ChromQuest Chromatography Data System (CDS) ... data acquisition, chromatography data processing and ... High Speed LC. The companys innovative ... maximize the benefits of Thermo Scientific ...
Biology Products: